Valneva (VALN) schedules March 18, 2026 webcast on full year 2025 results

Rhea-AI Filing Summary

Valneva SE, a specialty vaccine company, plans to report its full year 2025 consolidated financial results on March 18, 2026. The company will host a live webcast at 3 p.m. CET / 10 a.m. EDT to discuss the results and provide a business update.

The webcast will be available on Valneva’s website and archived after the event. The filing also reiterates Valneva’s focus on developing and commercializing vaccines for infectious diseases, including advanced candidates for Lyme disease and Shigella.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report: March 9, 2026

Commission File Number: 001-40377

Valneva SE

(Translation of registrant's name into English)

Îlot Saint-Joseph, Bureaux Convergence

12ter Quai Perrache

69002 Lyon, France

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On March 9, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1. The information contained in this Form 6-K is hereby incorporated by reference into the registrant's registration Statement on Form F-3 (File No. 333-268071).

Exhibit
Exhibit 99.1			Press release dated March 9, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Valneva SE (Registrant)

Date: March 9, 2026

/s/ Thomas Lingelbach

Thomas Lingelbach

Chief Executive Officer and President

Valneva to Report Full Year 2025 Consolidated Financial Results

on March 18, 2026

Lyon (France), March 9, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it will report its full year 2025 financial results on Wednesday, March 18, 2026. The Company will host a live webcast beginning at 3 p.m. CET/10 a.m. EDT to discuss the financial results and provide a business update.

The live webcast will be accessible on the Company’s website and made available as an archive after the event concludes. Please refer to this link: https://edge.media-server.com/mmc/p/qj2g7e52.

About Valneva SE

We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions.

We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines.

Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world’s most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats. More information is available at www.valneva.com.

Valneva Investor and Media Contacts Laetitia Bachelot-Fontaine VP, Global Communications and European Investor Relations M +33 (0)6 4516 7099 laetitia.bachelotfontaine@valneva.com Joshua Drumm, Ph.D. VP, Global Investor Relations M +001 917 815 4520 joshua.drumm@valneva.com

Forward-Looking Statements

This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to the progress, timing, results and completion of research, development and clinical trials for product candidates, to regulatory approval of product candidates and review of existing products, and financial guidance including projected product sales, total revenue and total R&D investments. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be sustained in the future. In some cases, you can identify forward-looking statements by words such as “could,” “should,” “may,” “expects,” “anticipates,” “believes,” “intends,” “estimates,” “aims,” “targets,” or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or

     VALNEVA SE

achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties and delays involved in the development and manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Valneva is providing this information as of the date of this press release and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

2

FAQ

When will Valneva (VALN) report its full year 2025 financial results?

Valneva will report its full year 2025 consolidated financial results on March 18, 2026. The company plans a same-day webcast to discuss results and provide a broader business update to stakeholders and investors.

What time is Valneva’s webcast for 2025 results and how can it be accessed?

Valneva’s webcast will begin at 3 p.m. CET / 10 a.m. EDT. It can be accessed via a live stream on the company’s website and will be archived online for later viewing after the event concludes.

What type of company is Valneva (VALN) according to this 6-K filing?

Valneva is described as a specialty vaccine company focused on prophylactic vaccines for infectious diseases with unmet medical needs. It develops, manufactures, and commercializes vaccines and currently markets three proprietary travel vaccines that support its ongoing R&D pipeline.

Which key vaccine candidates does Valneva highlight in this disclosure?

Valneva highlights an advanced Lyme disease vaccine candidate partnered with Pfizer and what it calls the world’s most clinically advanced Shigella vaccine candidate. It also notes additional vaccine candidates targeting other global public health threats in its development pipeline.

Will the March 18, 2026 Valneva webcast be available after it ends?

Yes, Valneva states that the live webcast will be archived on the company’s website after the event. This allows investors and other interested parties to replay the full year 2025 results discussion and business update at a later time.

What forward-looking statement cautions does Valneva include in this press release?

Valneva cautions that forward-looking statements about clinical progress, regulatory approvals and financial guidance involve risks and uncertainties. Actual results may differ due to clinical outcomes, regulatory actions, competition, currency fluctuations, credit conditions, and intellectual property challenges.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 10.2 KB